The unique biology of Plasmodium vivax, with its ability to form latent hypnozoites in the liver
stage and the early appearance of gametocytes during blood stage infection, makes it …

Plasmodium vivax continues to cause significant morbidity outside Africa with more than
50% of malaria cases in many parts of South and South-east Asia, Pacific islands, Central …

Introduction Plasmodium vivax causes significant public health problems in endemic
regions. A vaccine to prevent disease is critical, considering the rapid spread of drug …

Controlled Human Malaria Infection models (CHMI) have been critical to advancing new
vaccines for malaria. Stringent and safe preparation of a challenge agent is key to the …

Plasmodium vivax remains an important cause of morbidity and mortality across the
Americas, Horn of Africa, East and South East Asia. Control of transmission has been …

Plasmodium vivax parasites cause the majority of malaria cases outside Africa, and are
increasingly being acknowledged as a cause of severe disease. The unique attributes of P …

An estimated 229 million cases of malaria occurred worldwide in 2019. Both, Plasmodium
falciparum and P. vivax are responsible for most of the malaria disease burden in the world …

Preventing malaria infection through vaccination requires preventing every sporozoite
inoculated by mosquito bite: a major challenge for Plasmodium falciparum. Plasmodium …

Although Plasmodium falciparum is the leading cause of morbidity and mortality due to
malaria worldwide, nearly 2.5 billion people, mostly outside Africa, are also at risk from …

Latent forms of Plasmodium vivax, called hypnozoites, cause malaria relapses from the liver
into the bloodstream and are a major obstacle to malaria eradication. To experimentally …